# A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

> **NCT06971185** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 430 (estimated)

## Conditions studied

- Myelodysplastic Syndromes (MDS)

## Interventions

- **DRUG:** Luspatercept
- **DRUG:** Erythropoiesis-stimulating agent (ESA)

## Key facts

- **NCT ID:** NCT06971185
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06971185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06971185, "A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06971185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*